Medley EBIT Margin
The EBIT Margin (Operating Margin) of Medley (4480.T) as of Jul 26, 2026 is 5.84 %. In the previous year, EBIT Margin (Operating Margin) was 7.94 % — a change of -26.37% (lower).
Get this data via API
Financial Data API
EBIT Margin
5.84 %
YoY
-26.37%
Last updated:
EBIT Margin (Operating Margin) of Medley is 2026 5.84 % . EBIT Margin (Operating Margin) of Medley was 2025 7.94 % . It decreases by -26.37% lower compared to the previous year.
Medley's operating (EBIT) margin stands at 5.8%, broadly stable from 6.7% several years earlier.
Access this data via the Eulerpool API
Medley Stock analysis
What does Medley do? Medley Inc is a global company specializing in the production and sale of pharmaceutical products. The company was founded in 1985 as a small business and has since become a leading player in the pharmaceutical industry, operating in over 150 countries. Medley Inc produces a variety of products in different areas such as cardiology, gastroenterology, oncology, orthopedics, neurology, and dermatology. The company's business model is based on the development and sale of generic products, which are imitation products of patented drugs. Medley Inc focuses on producing high-quality and effective medicines at competitive prices. The company has production sites in various countries to meet the demand for drugs in each region. In addition to being a manufacturer of medicines, Medley Inc also offers services such as drug distribution, clinical studies, research and development, consulting for pharmaceutical manufacturers, and customer training. The company places great importance on the quality and safety of its products and services and has implemented a comprehensive quality management system to meet its high standards. The product range of Medley Inc includes a variety of drugs used in different indications, including well-known drugs such as Tamoxifen for cancer, Fluoxetine for depression, Oxycodone for pain relief, and Levofloxacin as an antibiotic. Medley Inc strives to make affordable medications accessible to all people and works to improve healthcare worldwide. The company has formed long-term partnerships with organizations and governments in emerging countries to enhance access to affordable medicines. Overall, Medley Inc is a significant player in the pharmaceutical industry, focusing on the production of generics and improving healthcare globally. Through its efforts in quality, innovation, and partnerships, the company aims to have a positive impact on society. Medley is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Medley stock
EBIT Margin (Operating Margin) of Medley is 5.84 % in 2026.
Access this data via the Eulerpool API
Margins — Medley
All Key Metrics — Medley
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth